SABS

SAB Biotherapeutics Inc. a clinical-stage biopharmaceutical company engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders including infectious diseases influenza CDI type 1 diabetes organ transplantation and oncology as well as immunology gastroenterology and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition its lead product candidates include SAB-185 a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176 a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics Inc. was founded in 2014 and is headquartered in Sioux Falls South Dakota.